NEXL's work in stem cell appears legitimate. Stem cells can be important therapy for blood disorders and transplantation. They seem to have good alliance. Other than that...I'm not sure. The float is huge. I think the whole biotech sector is just on fire and every company is just moving up regardless.
biz.yahoo.com
Company Press Release
SOURCE: Nexell Therapeutics Inc.
Nexell Therapeutics President McIntosh to Speak At BIO CEO & Investor Conference
IRVINE, Calif., Feb. 14 /PRNewswire/ -- Nexell Therapeutics Inc. (Nasdaq: NEXL - news), one of the world's leading suppliers of therapeutic and diagnostic products based on stem cell technology, today announced that L. William McIntosh, President and COO, will speak at the BIO CEO & Investor Conference at the Waldorf-Astoria Hotel in New York City on February 16 at 2:00 PM.
``This is an ideal time to address the investment community about the progress we've made in building the world's leading cell therapy company,' said McIntosh. ``The current interest in the dramatic promise of stem cell research for the future of medicine tends to obscure the fact that hematopoietic (blood) stem cell therapies are a commercial reality today. Nexell Therapeutics is making stem cell selection and expansion technologies available to doctors treating cancer patients around the world and we are rapidly accumulating unmatched expertise in harnessing the potential of living cells to treat a wide variety of other human diseases related to the blood and immune system.'
``We spent the majority of 1999 putting all the pieces in place to focus on our present commercial opportunity and rapidly bring other cell therapy applications to market,' McIntosh continued. ``As we entered 2000, we had an FDA-approved flagship product, the Isolex© Magnetic Cell Selection System, a direct sales organization and distribution system in both the U.S. and the E.U., a talented and operationally-focused management team and Board of Directors, a rationalized R&D strategy, and, having completed a $63 million private placement, adequate operating capital and no debt. Both the clinical community and our shareholders will reap the benefits of those accomplishments over the next several years.'
Nexell Therapeutics Inc.
Located in Irvine, California, Nexell Therapeutics Inc. (Nasdaq: NEXL - news) is a cell therapy company whose mission is to put the healing power of the cell into the hands of physicians. Nexell is developing and marketing innovative ex vivo cell therapies and in vitro diagnostics for cancer, autoimmune, metabolic and genetic diseases. Nexell's lead product, the Isolex© 300i Magnetic Cell Selection System, is the only FDA approved device commercially available for the selection of hematopoietic stem cells and the removal of tumor cells from autologous peripheral blood as a component of aggressive cancer treatment. In addition, Nexell markets the Cytonex(TM) ICC Staining Kit and an extensive line of cell therapy preparation, storage and expansion products including the Cryocyte(TM), SteriCell© and Lifecell© brands.
cbs.marketwatch.com
-- Nexell Therapeutics (NEXL: news, msgs) develops cell therapy toolkits to diagnose cancer and genetic diseases. Such diagnostic toolkits, which would be sold to doctors and labs, are a popular theme on Wall Street.
biz.yahoo.com
``Nexell is in a position to translate what the medical community is learning about the specific roles of different cells in the immune system into clinical scale cell therapy products,' said Dennis Van Epps, PhD, Vice President, Research, Nexell Therapeutics. ``Our work with these Diaclone antibodies will contribute to our progress in several important research programs aimed at new clinical applications for cell selection, including allogeneic (donor) transplants and dendritic cell vaccines.'
biz.yahoo.com
Tuesday December 7, 10:04 am Eastern Time
Company Press Release
NIH Researchers Use Cell Selection to Engineer Success With Mini Transplant Treatment for Rare Blood Disorder
Eight of Nine Patients Achieve Functioning, Chimeric Immune Systems From Sibling Stem Cell Grafts
IRVINE, Calif.--(BW HealthWire)--Dec. 7, 1999-- Researchers at the National Institutes of Health (NIH) have successfully corrected a rare blood disorder, chronic granulomatous disease (CGD), using a mini transplant conditioning regimen incorporating Isolex© stem cell selection technology to purge donor T-cells from the stem cell graft. This approach reduced both conditioning related toxicity and the severity of graft versus host disease (GVHD), which have limited the utility of donor stem cell transplantation in the treatment of inherited blood disorders. Initial data from a study of nine CGD patients were presented today in New Orleans, Louisiana, at the Annual Meeting of the American Society of Hematology by Mitchell E. Horwitz, MD, of the National Institute of Allergy and Infectious Diseases, part of the NIH.
biz.yahoo.com
Monday November 29, 8:32 am Eastern Time
Company Press Release
Nexell Therapeutics Completes $63 Million Financing
IRVINE, Calif.--(BUSINESS WIRE)--Nov. 29, 1999--Nexell Therapeutics Inc. (NASDAQ:NEXL - news), one of the world's leading suppliers of therapeutic and diagnostic products based on stem cell technology, announced today that it has raised $63 million in a private placement with institutional investors. The transaction is a structured financing consisting of a new Series B Preferred Stock, convertible into Nexell Common Stock at $2.75 per share, backed by put rights granted by Baxter International Inc. (NYSE:BAX - news), and certain warrants. The Company will use a portion of proceeds to retire approximately $34 million in convertible subordinated debentures held by Baxter and will use the remainder for general corporate purposes. |
